<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">RMD Open</journal-id><journal-id journal-id-type="iso-abbrev">RMD Open</journal-id><journal-id journal-id-type="hwp">rmdopen</journal-id><journal-id journal-id-type="publisher-id">rmdopen</journal-id><journal-title-group><journal-title>RMD Open</journal-title></journal-title-group><issn pub-type="epub">2056-5933</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29595841</article-id><article-id pub-id-type="pmc">5869210</article-id><article-id pub-id-type="publisher-id">rmdopen-2017-000582corr1</article-id><article-id pub-id-type="doi">10.1136/rmdopen-2017-000582corr1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group></article-categories><title-group><article-title>Correction: <italic>4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis</italic>
</article-title></title-group><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>26</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>3</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>1</issue><elocation-id>rmdopen-2017-000582corr1</elocation-id><permissions><copyright-statement>&#x000a9; Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="rmdopen-2017-000582corr1.pdf"/><related-article id="d35e68" related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1136/rmdopen-2017-000582"/><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>van der Heijde D, Deodhar A, FitzGerald O, <italic>et al</italic>. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. <italic>RMD Open</italic> 2018;4:<related-article id="d35e84" related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1136/rmdopen-2017-000582">e000582</related-article>. doi: 10.1136/rmdopen-2017-000582.</p><p>Several changes were inadvertently missed during the production stage. These corrections are now incorporated into the current version.</p></body></article>